Illumina, Inc., a global leader in DNA sequencing and array-based technologies, has announced significant changes to its executive management team. Joydeep Goswami, who has been with the company since 2019, will be leaving his roles as Chief Financial Officer and Chief Strategy and Development Officer. Ankur Dhingra will take over as the new CFO starting April 15, 2024, bringing extensive experience from his previous roles at Summit Therapeutics Inc., CareDx, and Agilent Technologies. Dhingra's appointment comes with a comprehensive compensation package, including a base salary, variable compensation, equity awards, and additional benefits. Jakob Wedel has been appointed as Chief Strategy and Corporate Development Officer, a role previously held by Goswami. Wedel, who joined Illumina in November 2023, has a strong background in...Show More

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, has announced significant changes to its executive management team. Joydeep Goswami, who has been with the company since 2019, will be leaving his roles as Chief Financial Officer and Chief Strategy and Development Officer. Ankur Dhingra will take over as the new CFO starting April 15, 2024, bringing extensive experience from his previous roles at Summit Therapeutics Inc., CareDx, and Agilent Technologies. Dhingra's appointment comes with a comprehensive compensation package, including a base salary, variable compensation, equity awards, and additional benefits. Jakob Wedel has been appointed as Chief Strategy and Corporate Development Officer, a role previously held by Goswami. Wedel, who joined Illumina in November 2023, has a strong background in strategy, having worked with global consulting firms and co-founding a strategy firm. Goswami will remain in an advisory capacity until June 30 to assist with the transition. Illumina also reaffirmed its financial guidance for Q1 2024 and the full year, as previously announced in February 2024. The company's leadership changes and financial outlook were disclosed in a press release on April 9, 2024.